Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 10/2018

01-10-2018 | Original Research Paper

Micronized palmitoylethanolamide reduces joint pain and glial cell activation

Authors: Maria Lavinia Bartolucci, Ida Marini, Francesco Bortolotti, Daniela Impellizzeri, Rosanna Di Paola, Giuseppe Bruschetta, Rosalia Crupi, Marco Portelli, Angela Militi, Giacomo Oteri, Emanuela Esposito, Salvatore Cuzzocrea

Published in: Inflammation Research | Issue 10/2018

Login to get access

Abstract

Objective and design

Temporomandibular disorder (TMD) is a common painful condition in the temporomandibular joint (TMJ). Joint inflammation is believed to be a chief cause of pain in patients with TMD, through the release of pro-inflammatory cytokines that induce peripheral sensitization of nerve terminals followed by microglial stimulation.

Materials and subject

TMJ was induced in rats with the injection of complete Freund’s adjuvant (CFA) emulsion into the left TMJ capsule.

Treatment

The present study would assess the effects of micronized palmitoylethanolamide (m-PEA) on glial activation and trigeminal hypersensitivity.

Methods

Ten mg/kg m-PEA or corresponding vehicle was administered 1 h after CFA and mechanical allodynia and edema were evaluated at 24 and 72 h after CFA injection.

Results

CFA-injected animals showed TMJ edema and ipsilateral mechanical allodynia accompanied by a robust growth in GFAP protein-positive satellite glial cells and activation of resident macrophages in the TG. Moreover, m-PEA administration significantly reduced the degree of TMJ damage and pain, macrophage activation in TG and up-regulation of Iba1.

Conclusions

The results confirm that m-PEA could represent a novel approach for monitoring pain during trigeminal nerve sensitization.
Literature
1.
Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis: a critical review of the state-of-the-art, current prospects, and future challenges. Bone. 2016;85:81–90.CrossRefPubMed
2.
Fusco M, Skaper SD, Coaccioli S, Varrassi G, Paladini A. Degenerative joint diseases and neuroinflammation. Pain Pract. 2017;17:522–32.CrossRefPubMed
3.
Wang XD, Zhang JN, Gan YH, Zhou YH. Current understanding of pathogenesis and treatment of TMJ osteoarthritis. J Dent Res. 2015;94:666–73.CrossRefPubMed
4.
Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3–S14.CrossRef
5.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73.CrossRefPubMedPubMedCentral
6.
Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22:79–94.CrossRefPubMed
7.
Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain. Int Rev Neurobiol. 2011;97:179–206.CrossRefPubMed
8.
Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23 (discussion 24–5).CrossRefPubMedPubMedCentral
9.
Villa G, Ceruti S, Zanardelli M, Magni G, Jasmin L, Ohara PT, et al. Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. Mol Pain. 2010;6:89.CrossRefPubMedPubMedCentral
10.
Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflamm. 2013;10:91.
11.
Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflamm. 2014;11:136.CrossRef
12.
Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A, et al. Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther. 2013;15:R192.CrossRefPubMedPubMedCentral
13.
De Filippis D, D’Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T. Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. J Cell Mol Med. 2009;13:1086–95.CrossRefPubMed
14.
Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, et al. Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflamm. 2013;10:20.
15.
Flake NM, Bonebreak DB, Gold MS. Estrogen and inflammation increase the excitability of rat temporomandibular joint afferent neurons. J Neurophysiol. 2005;93:1585–97.CrossRefPubMed
16.
Ren K. An improved method for assessing mechanical allodynia in the rat. Physiol Behav. 1999;67:711–6.CrossRefPubMed
17.
Takeda M, Tanimoto T, Nasu M, Matsumoto S. Temporomandibular joint inflammation decreases the voltage-gated K + channel subtype 1.4-immunoreactivity of trigeminal ganglion neurons in rats. Eur J Pain. 2008;12:189–95.CrossRefPubMed
18.
Schutz TC, Andersen ML, Silva A, Tufik S. Distinct gender-related sleep pattern in an acute model of TMJ pain. J Dent Res. 2009;88:471–6.CrossRefPubMed
19.
Zhou Q, Imbe H, Dubner R, Ren K. Persistent Fos protein expression after orofacial deep or cutaneous tissue inflammation in rats: implications for persistent orofacial pain. J Comp Neurol. 1999;412:276–91.CrossRefPubMed
20.
Wang S, Song L, Tan Y, Ma Y, Tian Y, Jin X, et al. A functional relationship between trigeminal astroglial activation and NR1 expression in a rat model of temporomandibular joint inflammation. Pain Med. 2012;13:1590–600.CrossRefPubMedPubMedCentral
21.
Raghavendra V, Tanga FY, DeLeo JA. Complete Freund’s adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004;20:467–73.CrossRefPubMed
22.
Chiang CY, Dostrovsky JO, Iwata K, Sessle BJ. Role of glia in orofacial pain. Neurosci. 2011;17:303–20.
23.
Iwata K, Imamura Y, Honda K, Shinoda M. Physiological mechanisms of neuropathic pain: the orofacial region. Int Rev Neurobiol. 2011;97:227–50.CrossRefPubMed
24.
Bonezzi FT, Sasso O, Pontis S, Realini N, Romeo E, Ponzano S, et al. An important role for N-acylethanolamine acid amidase in the complete freund’s adjuvant rat model of arthritis. J Pharmacol Exp Ther. 2016;356:656–63.CrossRefPubMed
25.
Cairns BE, Laursen JC, Dong XD, Gazerani P. Intraganglionic injection of a nitric oxide donator induces afferent mechanical sensitization that is attenuated by palmitoylethanolamide. Cephalalgia. 2014;34:686–94.CrossRefPubMed
26.
Laursen JC, Cairns BE, Kumar U, Somvanshi RK, Dong XD, Arendt-Nielsen L, et al. Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate. Int J Physiol Pathophysiol Pharmacol. 2013;5:228–38.PubMedPubMedCentral
27.
Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick MR, et al. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol Pain. 2009;5:35.CrossRefPubMedPubMedCentral
28.
Rao S, Song Y, Peddie F, Evans AM. Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int J Nanomed. 2011;6:1245–51.CrossRef
29.
30.
Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997;272:3315–23.CrossRefPubMed
31.
Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology. 2008;54:16–22.CrossRefPubMed
32.
Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med. 2011;15:2664–74.CrossRefPubMedPubMedCentral
33.
Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133:9–15.CrossRefPubMed
34.
Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013;48:340–52.CrossRefPubMed
35.
Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targ. 2013;12:45–54.CrossRef
36.
Calabro RS, Bramanti P. Occipital neuralgia responding to palmitoylethanolamide. Headache. 2017;57:E23–E24.CrossRef
37.
Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26:99–104.PubMed
Metadata
Title
Micronized palmitoylethanolamide reduces joint pain and glial cell activation
Authors
Maria Lavinia Bartolucci
Ida Marini
Francesco Bortolotti
Daniela Impellizzeri
Rosanna Di Paola
Giuseppe Bruschetta
Rosalia Crupi
Marco Portelli
Angela Militi
Giacomo Oteri
Emanuela Esposito
Salvatore Cuzzocrea
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 10/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-018-1179-y

Other articles of this Issue 10/2018

Inflammation Research 10/2018 Go to the issue

Review

Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function

Original Research Paper

Lysosomal membrane permeabilization causes secretion of IL-1β in human vascular smooth muscle cells

Original Research Paper

Quetiapine ameliorates collagen-induced arthritis in mice via the suppression of the AKT and ERK signaling pathways

Review

Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer

Original Research Paper

Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model

Original Research Paper

Reduced intestinal epithelial mitochondrial function enhances in vitro interleukin-8 production in response to commensal Escherichia coli
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits